Partner Content Partner Content FDA releases Biosimilar Action Plan: Hear more at Biosimilar... Biosimilars USA conference information
Partner Content Partner Content SMi’s Biosimilars & Biobetters - Exclusive Interview with Dr... Biosimilars & Biobetters conference information
Events Partner Content SMi's 9th annual Biosimilars & Biobetters Biosimilars & Biobetters conference information
Events Partner Content SMi's 5th Annual Biosimilars USA Conference Biosimilars USA conference information
Partner Content Partner Content Registration is open for the 9th Annual Biosimilars & Bi... Biosimilars & Biobetters conference information
Partner Content Partner Content Agenda Released for USA Biosimilars Conference this November Agenda Released for USA Biosimilars Conference this Nov
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.